# A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

Source: https://onco.cc/trials/nct06464991/  
OnCo record `nct06464991` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Equecabtagene autoleucel, Daratumumab, Pomalidomide in multiple myeloma, run by Nanjing IASO Biotechnology Co., Ltd., now recruiting.

## Summary

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) is a phase 3 interventional study registered as NCT06464991 by Nanjing IASO Biotechnology Co., Ltd., with 240 participants planned, started 2024-03-27 and due to reach its primary completion in 2027-08. Interventions recorded: Equecabtagene Autoleucel Injection, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06464991
- Phase: 3
- Setting: A Phase III Randomized, Controlled Study of Equecabtagene Autoleucel Injection in Subjects With Lenalidomide-Refractory R/R Multiple Myeloma
- Sponsor: Nanjing IASO Biotechnology Co., Ltd.
- Enrolled: 240

## Sources

- ClinicalTrials.gov NCT06464991: https://clinicaltrials.gov/study/NCT06464991

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Bortezomib](https://onco.cc/drugs/bortezomib/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Equecabtagene autoleucel](https://onco.cc/drugs/equecabtagene-autoleucel/), [Pomalidomide](https://onco.cc/drugs/pomalidomide/)

---
JSON: https://onco.cc/api/v1/entities/nct06464991.json